Update on toll-like receptor-directed therapies for human disease. (12th October 2007)

• Record Type: Journal Article
• Authors: Tse, Kevin; Horner, Anthony A
• Is Part Of: Annals of the rheumatic diseases. Volume 66(2007)Supplement 3
• Page Start: iii77
• Page End: iii80
• Publication Date: 2007-10-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/ard.2007.078998
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.